fda warning bpc-157 unapproved new drug Peptide Compounding Vote Raises Questions for Developers FDA Advisory Committee Recommends Adding

A rodent-based thyroid boxed warning carries no human signal at trial resolution, with a personal or family history of medullary thyroid cancer or MEN2 as a contraindication

The only thing I would complain about is the inconsistency between each pharmacy

Data Submission and Reporting Requirements for the Information Transfer PRO-PM In the CY 2026 OPPS/ASC proposed rule, we discussed the proposed adoption of the Information Transfer PRO-PM beginning with voluntary reporting for the CY 2027 and CY 2028 reporting periods followed by mandatory reporting beginning with the CY 2029 reporting period/CY 2031 payment determination (90 FR 33776 through 33779)

- Not feeling tired - Kick diseases' butt